NEW YORK (GenomeWeb News) — EuroGentest is expected to announce next week that it is evaluating a pyrophosphorolysis activated polymerization assay for prenatal screening through Europe’s Special Non-invasive Advances in Fetal and NeoNatal Evaluation Network (SAFE) and another of its Excellence programs.
 
The PAP assay, a non-invasive prenatal screening test, uses maternal plasma to detect rare mutations and to determine fetal sex.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.